|
1
|
Mehanna H, Paleri V, West CM and Nutting
C: Head and neck cancer - Part 1: epidemiology, presentation, and
prevention. BMJ. 341:c46842010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Maden C, Beckmann AM, Thomas DB, McKnight
B, Sherman KJ, Ashley RL, et al: Human papillomaviruses, herpes
simplex viruses, and the risk of oral cancer in men. Am J
Epidemiol. 135:1093–1102. 1992.PubMed/NCBI
|
|
3
|
Wagenblast J, Hambek M, Baghi M, Gstottner
W, Strebhardt K, Ackermann H, et al: Antiproliferative activity of
bortezomib alone and in combination with cisplatin or docetaxel in
head and neck squamous cell carcinoma cell lines. J Cancer Res Clin
Oncol. 134:323–330. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Renner AG, Dos Santos C, Recher C, Bailly
C, Creancier L, Kruczynski A, et al: Polo-like kinase 1 is
overexpressed in acute myeloid leukemia and its inhibition
preferentially targets the proliferation of leukemic cells. Blood.
114:659–662. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Van de Weerdt BC and Medema RH: Polo-like
kinases: a team in control of the division. Cell Cycle. 5:853–864.
2006.PubMed/NCBI
|
|
6
|
Steegmaier M, Hoffmann M, Baum A, Lenart
P, Petronczki M, Krssak M, et al: BI 2536, a potent and selective
inhibitor of polo-like kinase 1, inhibits tumor growth in vivo.
Curr Biol. 17:316–322. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Takai N, Hamanaka R, Yoshimatsu J and
Miyakawa I: Polo-like kinases (Plks) and cancer. Oncogene.
24:287–291. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Strebhardt K and Ullrich A: Targeting
polo-like kinase 1 for cancer therapy. Nat Rev Cancer. 6:321–330.
2006. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Datta D, Banerjee P, Gasser M,
Waaga-Gasser AM and Pal S: CXCR3-B can mediate growth-inhibitory
signals in human renal cancer cells by down-regulating the
expression of heme oxygenase-1. J Biol Chem. 285:36842–36848. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ray RB, Raychoudhuri A, Steele R and
Nerurkar P: Bitter melon (Momordica charantia) extract
inhibits breast cancer cell proliferation by modulating cell cycle
regulatory genes and promotes apoptosis. Cancer Res. 70:1925–1931.
2010.PubMed/NCBI
|
|
11
|
Holtrich U, Wolf G, Brauninger A, Karn T,
Bohme B, Rubsamen-Waigmann H, et al: Induction and down-regulation
of PLK, a human serine/threonine kinase expressed in proliferating
cells and tumors. Proc Natl Acad Sci USA. 91:1736–1740. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wolf G, Elez R, Doermer A, Holtrich U,
Ackermann H, Stutte HJ, et al: Prognostic significance of polo-like
kinase (PLK) expression in non-small cell lung cancer. Oncogene.
14:543–549. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Knecht R, Elez R, Oechler M, Solbach C,
von Ilberg C and Strebhardt K: Prognostic significance of polo-like
kinase (PLK) expression in squamous cell carcinomas of the head and
neck. Cancer Res. 59:2794–2797. 1999.PubMed/NCBI
|
|
14
|
Jemal A, Murray T, Ward E, Samuels A,
Tiwari RC, Ghafoor A, et al: Cancer statistics. CA Cancer J Clin.
55:10–30. 2005.
|
|
15
|
Wagenblast J, Baghi M, Arnoldner C, Bisdas
S, Gstottner W, Ackermann H, et al: Cetuximab enhances the efficacy
of bortezomib in squamous cell carcinoma cell lines. J Cancer Res
Clin Oncol. 135:387–393. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Schoffski P, Blay JY, De Greve J, Brain E,
Machiels JP, Soria JC, et al: Multicentric parallel phase II trial
of the polo-like kinase 1 inhibitor BI 2536 in patients with
advanced head and neck cancer, breast cancer, ovarian cancer, soft
tissue sarcoma and melanoma. The first protocol of the European
Organization for Research and Treatment of Cancer (EORTC) Network
Of Core Institutes (NOCI). Eur J Cancer. 46:2206–2215. 2010.
|
